Comparative Pharmacology
Head-to-head clinical analysis: AVANDIA versus BYDUREON PEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVANDIA versus BYDUREON PEN.
AVANDIA vs BYDUREON PEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective agonist at peroxisome proliferator-activated receptor gamma (PPARγ), increasing insulin sensitivity in adipose tissue, skeletal muscle, and liver.
Glucagon-like peptide-1 (GLP-1) receptor agonist; increases insulin secretion, suppresses glucagon release, slows gastric emptying, and promotes satiety.
Initial dose 4 mg orally once daily; may increase to 8 mg once daily or 4 mg twice daily if inadequate glycemic control after 8-12 weeks. Maximum dose 8 mg/day.
2 mg subcutaneously once every 7 days (weekly)
None Documented
None Documented
3-4 hours (terminal elimination half-life). No clinically significant accumulation with once-daily dosing.
Terminal elimination half-life is 2.4 hours following subcutaneous administration; due to extended-release microspheres, systemic exposure is sustained over 10 weeks with multiple dosing (effective half-life ~2 weeks).
Primarily hepatic metabolism via CYP2C8, with minimal renal excretion of unchanged drug (<1%). Approximately 64% of the dose is excreted in urine as metabolites and 23% in feces as metabolites.
Renal excretion of intact exenatide via glomerular filtration and proteolytic degradation; approximately 100% of administered dose eliminated via renal pathways (urine) as intact peptide and metabolites.
Category C
Category C
Antidiabetic
Antidiabetic